FDA Approves $11,000 Cheaper Hepatitis C Drug

December 20, 2014 1:04 PM

4 0

On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie’s Viekira Pak, a new hepatitis C cure, that will challenge Gilead Sciences’ more expensive cure. Both FDA and Medicaid programs hoped that the new drug would bring some real competition in hepatitis C drug market.

However, there wasn’t much improvement, since AbbVie is going to sell a 12-week kit of the new drug for $83,319. Although it is about $11,000 cheaper than Gilead’s Harvoni, Viekira Pak is still pricey.

Read more

To category page